Jordan Christensen
@jaysee.bsky.social
Reposted by Jordan Christensen
Determining the best AI tools & investing significantly in culture are key themes for 2025, Chief People & Impact Officer Erica Fox told @fastcompany.com. Erica was 1 of 15 HR leaders interviewed about her 2025 predictions for the future of work. More: www.fastcompany.com/91248622/hr-... #techbio
From AI to RTO, 15 HR leaders share their future of work predictions for 2025
As HR leaders look ahead to the new year, here's what they expect employers will prioritize when it comes to the future of work.
www.fastcompany.com
January 3, 2025 at 3:48 PM
Determining the best AI tools & investing significantly in culture are key themes for 2025, Chief People & Impact Officer Erica Fox told @fastcompany.com. Erica was 1 of 15 HR leaders interviewed about her 2025 predictions for the future of work. More: www.fastcompany.com/91248622/hr-... #techbio
Reposted by Jordan Christensen
Today at the @theaacr.bsky.social Special Conference in Cancer Research, our CSO David Hallett, PhD shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. Here's what was revealed. 🧵
December 9, 2024 at 11:12 PM
Today at the @theaacr.bsky.social Special Conference in Cancer Research, our CSO David Hallett, PhD shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. Here's what was revealed. 🧵
Reposted by Jordan Christensen
📣 Announcing the first patient dosed in our Phase 1/2 clinical study of REC-1245 - a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma and the first program to emerge from end-to-end use of the RecursionOS. #techbio More: ir.recursion.com/news-release...
December 3, 2024 at 1:41 PM
📣 Announcing the first patient dosed in our Phase 1/2 clinical study of REC-1245 - a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma and the first program to emerge from end-to-end use of the RecursionOS. #techbio More: ir.recursion.com/news-release...
I just completed "Historian Hysteria" - Day 1 - Advent of Code 2024 #AdventOfCode adventofcode.com/2024/day/1
December 1, 2024 at 5:33 PM
I just completed "Historian Hysteria" - Day 1 - Advent of Code 2024 #AdventOfCode adventofcode.com/2024/day/1
Reposted by Jordan Christensen
How the combination deal makes us a "trans-Atlantic #AI powerhouse" w/ "a pipeline of more than 10 clinical & preclinical programs" incl REC-617, CDK7 inhibitor for advanced solid tumors. PH I safety & PK/PD data coming Dec. 9 at
@theaacr.bsky.social; webinar Dec. 10. genengnews.com/topics/artif...
@theaacr.bsky.social; webinar Dec. 10. genengnews.com/topics/artif...
Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine
Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug discov...
genengnews.com
November 25, 2024 at 2:34 PM
How the combination deal makes us a "trans-Atlantic #AI powerhouse" w/ "a pipeline of more than 10 clinical & preclinical programs" incl REC-617, CDK7 inhibitor for advanced solid tumors. PH I safety & PK/PD data coming Dec. 9 at
@theaacr.bsky.social; webinar Dec. 10. genengnews.com/topics/artif...
@theaacr.bsky.social; webinar Dec. 10. genengnews.com/topics/artif...
Reposted by Jordan Christensen
Introducing a new #TechBio powerhouse. Our expanded clinical pipeline & partnerships puts us on par with many mid-sized pharma companies, while our combined platforms – bringing together the best of digital biology & chemistry w/ pharma's fastest supercomputer – allow us to rapidly iterate & scale.
November 20, 2024 at 5:38 PM
Introducing a new #TechBio powerhouse. Our expanded clinical pipeline & partnerships puts us on par with many mid-sized pharma companies, while our combined platforms – bringing together the best of digital biology & chemistry w/ pharma's fastest supercomputer – allow us to rapidly iterate & scale.
Reposted by Jordan Christensen
Why Recursion Pharmaceuticals abandoned cell painting for brightfield imaging
www.owlposting.com/p/why-recurs...
After over a decade,Recursion Pharmaceuticals changed its primary assay. Why is that? I answer that question over 5.6k words (26 minutes to read)
first journalism-y piece!
www.owlposting.com/p/why-recurs...
After over a decade,Recursion Pharmaceuticals changed its primary assay. Why is that? I answer that question over 5.6k words (26 minutes to read)
first journalism-y piece!
Why Recursion Pharmaceuticals abandoned cell painting for brightfield imaging
5.7k words, 26 minutes reading time
www.owlposting.com
November 8, 2024 at 3:59 PM
Why Recursion Pharmaceuticals abandoned cell painting for brightfield imaging
www.owlposting.com/p/why-recurs...
After over a decade,Recursion Pharmaceuticals changed its primary assay. Why is that? I answer that question over 5.6k words (26 minutes to read)
first journalism-y piece!
www.owlposting.com/p/why-recurs...
After over a decade,Recursion Pharmaceuticals changed its primary assay. Why is that? I answer that question over 5.6k words (26 minutes to read)
first journalism-y piece!